This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (193)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Women's Health  • Pregnancy and Breast Feeding  • Alert me on articles by topic  Social Bookmarking   What's this?

A Prospective Controlled Multicenter Study

Nathalie A. Kulin, MSc; Anne Pastuszak, MSc; Suzanne R. Sage, RN, MS; Betsy Schick-Boschetto, MSN; Glenda Spivey, MS, CT; Marcia Feldkamp; Kelly Ormond, MS; Doreen Matsui, MD; Amy K. Stein-Schechman, MS; Lola Cook, MS; Joanne Brochu; Michael Rieder, MD; Gideon Koren, MD

JAMA. 1998;279:609-610.

Context.— Although a large number of women of reproductive age use new selective serotonin reuptake inhibitors (SSRIs) and half of all pregnancies are unplanned, no data exist on the safety of these agents for the human fetus.

Objective.— To assess fetal safety and risk of fluvoxamine, paroxetine, and sertraline.

Design.— A prospective, multicenter, controlled cohort study.

Setting.— Nine Teratology Information Service centers in the United States and Canada.

Patients.— All women who were counseled during pregnancy following exposure to a new SSRI and followed up by the participating centers. Controls were randomly selected from women counseled after exposure to nonteratogenic agents.

Main Outcome Measures.— Rates of major congenital malformations.

Results.— A total of 267 women exposed to an SSRI and 267 controls were studied. Exposure to SSRIs was not associated with either increased risk for major malformations (9/222 live births [4.1%] vs 9/235 live births [3.8%] in the controls, relative risk, 1.06, 95% confidence interval, 0.43-2.62) or higher rates of miscarriage, stillbirth, or prematurity. Mean (SD) birth weights among SSRI users (3439 [505] g) were similar to the controls (3445 [610] g) as were the gestational ages (39.4 [1.7] weeks vs 39.4 [1.9] weeks).

Conclusion.— The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses.

From The Motherisk Program, The Hospital for Sick Children, and the University of Toronto, Toronto, Ontario (Mss Kulin and Pastuszak and Dr Koren); Teratogen Information Service, Tampa, Fla (Ms Sage); Pregnancy Healthline at Pennsylvania Hospital, Philadelphia (Ms Schick-Boschetto); Connecticut Pregnancy Exposure Information Service, Farmington, Conn (Mss Spivey and Brochu); Pregnancy Riskline, Salt Lake City, Utah (Ms Feldkamp); Department of Pediatrics, University of Vermont, College of Medicine, Burlington (Ms Ormond); FRAME Program, London, Ontario (Drs Matsui and Rieder); Illinois Teratogen Information Service, Chicago, Ill (Ms Stein-Schechman); and Indiana Teratogen Information Service, Indianapolis, Ind (Ms Cook).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Risk of Fetal Anomalies With Exposure to Selective Serotonin Reuptake Inhibitors
Lynn R. Grush, Andrea G. Witlin, and Gideon Koren
JAMA. 1998;279(23):1873.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Women should give informed consent before starting SSRIs
Mangin
BMJ 2009;339:b4292-b4292.
FULL TEXT  

Selective Serotonin Reuptake Inhibitor Exposure In Utero and Pregnancy Outcomes
Lund et al.
Arch Pediatr Adolesc Med 2009;163:949-954.
ABSTRACT | FULL TEXT  

Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes
Wisner et al.
Focus 2009;7:374-384.
ABSTRACT | FULL TEXT  

Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes
Wisner et al.
Am. J. Psychiatry 2009;166:557-566.
ABSTRACT | FULL TEXT  

Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension
Toh et al.
Am. J. Psychiatry 2009;166:320-328.
ABSTRACT | FULL TEXT  

Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy
Einarson et al.
Am. J. Psychiatry 2008;165:749-752.
ABSTRACT | FULL TEXT  

Duration of antidepressant use during pregnancy and risk of major congenital malformations
Ramos et al.
Br. J. Psychiatry 2008;192:344-350.
ABSTRACT | FULL TEXT  

Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of Preterm Birth
Suri et al.
Am. J. Psychiatry 2007;164:1206-1213.
ABSTRACT | FULL TEXT  

First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
Louik et al.
NEJM 2007;356:2675-2683.
ABSTRACT | FULL TEXT  

Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
Alwan et al.
NEJM 2007;356:2684-2692.
ABSTRACT | FULL TEXT  

Potential Medical and Surgical Complications of Serotonergic Antidepressant Medications
Looper
Psychosomatics 2007;48:1-9.
ABSTRACT | FULL TEXT  

Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
Ferreira et al.
Pediatrics 2007;119:52-59.
ABSTRACT | FULL TEXT  

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.
Oberlander et al.
Arch Gen Psychiatry 2006;63:898-906.
ABSTRACT | FULL TEXT  

Neonatal Abstinence Syndrome After In Utero Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants
Levinson-Castiel et al.
Arch Pediatr Adolesc Med 2006;160:173-176.
ABSTRACT | FULL TEXT  

Antidepressant Drug Use in Pregnancy
Niebyl
Reproductive Sciences 2005;12:297-297.
 

Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors: Literature Review and Implications for Clinical Applications
Moses-Kolko et al.
JAMA 2005;293:2372-2383.
ABSTRACT | FULL TEXT  

Antidepressant Use During Pregnancy and the Rates of Spontaneous Abortions: A Meta-Analysis
Hemels et al.
The Annals of Pharmacotherapy 2005;39:803-809.
ABSTRACT | FULL TEXT  

Depression and the Decision to Abort
SURI et al.
Am. J. Psychiatry 2004;161:1502-1502.
FULL TEXT  

Discontinuation Syndrome Following Late Pregnancy Exposure to Antidepressants
Koren
Arch Pediatr Adolesc Med 2004;158:307-308.
FULL TEXT  

Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy
Kallen
Arch Pediatr Adolesc Med 2004;158:312-316.
ABSTRACT | FULL TEXT  

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Costa et al.
Pharmacol. Rev. 2004;56:103-147.
ABSTRACT | FULL TEXT  

STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP
Kim et al.
Drug Metab. Dispos. 2004;32:212-221.
ABSTRACT | FULL TEXT  

Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
Zeskind and Stephens
Pediatrics 2004;113:368-375.
ABSTRACT | FULL TEXT  

Psychotropic medication in pregnancy
Kohen
Adv. Psychiatr. Treat. 2004;10:59-66.
ABSTRACT | FULL TEXT  

Effects of Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy on Serotonergic Symptoms in Newborns and Cord Blood Monoamine and Prolactin Concentrations
Laine et al.
Arch Gen Psychiatry 2003;60:720-726.
ABSTRACT | FULL TEXT  

Outcomes of Prenatal Antidepressant Exposure
Simon et al.
Am. J. Psychiatry 2002;159:2055-2061.
ABSTRACT | FULL TEXT  

Child Development Following Exposure to Tricyclic Antidepressants or Fluoxetine Throughout Fetal Life: A Prospective, Controlled Study
Nulman et al.
Am. J. Psychiatry 2002;159:1889-1895.
ABSTRACT | FULL TEXT  

Perinatal Outcome Following Third Trimester Exposure to Paroxetine
Costei et al.
Arch Pediatr Adolesc Med 2002;156:1129-1132.
ABSTRACT | FULL TEXT  

Management of Major Depression During Pregnancy
Hendrick and Altshuler
Am. J. Psychiatry 2002;159:1667-1673.
FULL TEXT  

An Open Trial of Morning Light Therapy for Treatment of Antepartum Depression
Oren et al.
Am. J. Psychiatry 2002;159:666-669.
ABSTRACT | FULL TEXT  

Depression in Women across the Life Cycle
Moore and Emanuel
Journal of Pharmacy Practice 2001;14:511-525.
ABSTRACT  

Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study
Einarson et al.
Am. J. Psychiatry 2001;158:1728-1730.
ABSTRACT | FULL TEXT  

Barrel Pattern Formation Requires Serotonin Uptake by Thalamocortical Afferents, and Not Vesicular Monoamine Release
Persico et al.
J. Neurosci. 2001;21:6862-6873.
ABSTRACT | FULL TEXT  

Risk-Benefit Decision Making for Treatment of Depression During Pregnancy
Wisner et al.
Am. J. Psychiatry 2000;157:1933-1940.
ABSTRACT | FULL TEXT  

Use of Psychoactive Medication During Pregnancy and Possible Effects on the Fetus and Newborn
Committee on Drugs
Pediatrics 2000;105:880-887.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment of Depression During Pregnancy
Wisner et al.
JAMA 1999;282:1264-1269.
ABSTRACT | FULL TEXT  

Diagnosis of Attention-Deficit/Hyperactivity Disorder and Use of Psychotropic Medication in Very Young Children
Rappley et al.
Arch Pediatr Adolesc Med 1999;153:1039-1045.
ABSTRACT | FULL TEXT  

Risk of Fetal Anomalies With Exposure to Selective Serotonin Reuptake Inhibitors
Grush et al.
JAMA 1998;279:1873-1873.
FULL TEXT  

Use of Serotonin Reuptake Inhibitors by Women of Childbearing Potential
Goldstein et al.
JAMA 1998;279:1873-1874.
FULL TEXT  

Use of New SSRIs in Pregnancy Appears Safe
JWatch Psychiatry 1998;1998:14-14.
FULL TEXT  

Use of New SSRIs in Pregnancy Appears Safe
JWatch General 1998;1998:1-1.
FULL TEXT